NR4A1 and breast cancer: In the last decades, several ETs have been introduced in the management of hormone receptor-positive human epidermal growth factor receptor 2 (HER2)-negative (luminal-like) BC, including aromatase inhibitors (AIs), selective estrogen receptor modulators (SERM), and degraders (SERD), that dramatically decreased mortality (1–3).